Historique
Article de Périodique
Effect of cannabidiol and Delta9-tetrahydrocannabinol on driving performance: A randomized clinical trial (2020)
Auteur(s) :
ARKELL, T. R. ;
VINCKENBOSCH, F. ;
KEVIN, R. C. ;
THEUNISSEN, E. L. ;
MCGREGOR, I. S. ;
RAMAEKERS, J. G.
Année
2020
Page(s) :
2177-2186
Langue(s) :
Anglais
Refs biblio. :
36
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus mots-clés
CANNABINOIDES
;
CANNABIDIOL
;
TETRAHYDROCANNABINOL
;
CONDUITE DE VEHICULE
;
ETUDE RANDOMISEE
;
CANNABIS
;
PERFORMANCE
;
COMPARAISON
;
TEST
;
COGNITION
;
PSYCHOMOTRICITE
Thésaurus géographique
PAYS-BAS
Note générale :
Editorial: Cole T.B., Saitz R. Cannabis and impaired driving. JAMA, 2020, Vol. 324, n° 21, p. 2163-2164. https://doi.org/10.1001/jama.2020.18544
Rubin R. Driving under the influence of CBD or THC - Is there a difference? JAMA, 2020, Vol. 324, n° 21, p. 2144-2145. https://doi.org/10.1001/jama.2020.22181
Rubin R. Driving under the influence of CBD or THC - Is there a difference? JAMA, 2020, Vol. 324, n° 21, p. 2144-2145. https://doi.org/10.1001/jama.2020.22181
Résumé :
Question: What is the magnitude and duration of driving impairment following vaporization of cannabis containing varying concentrations of Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD)?
Findings: In this crossover clinical trial that included 26 healthy participants who underwent on-road driving tests, the standard deviation of lateral position (SDLP, a measure of lane weaving, swerving, and overcorrecting) at 40 to 100 minutes following vaporized consumption was 18.21 cm for CBD-dominant cannabis, 20.59 cm for THC-dominant cannabis, 21.09 cm for THC/CBD-equivalent cannabis, and was 18.26 cm for placebo. At 240 to 300 minutes, the SDLP was 19.03 cm for CBD-dominant cannabis, 20.59 cm for THC-dominant cannabis, 19.88 cm for THC/CBD-equivalent cannabis, and 19.37 cm for placebo. Compared with placebo, SDLP with THC-dominant and THC/CBD-equivalent cannabis was significantly greater at 40 to 100 minutes but not 240 to 300 minutes after consumption; there were no significant differences between CBD-dominant cannabis and placebo.
Meaning: Although this study did not find statistically significant differences in driving performance during experimental on-road driving tests between CBD-dominant cannabis and placebo, the effect size may not have excluded clinically important impairment, and the doses tested may not necessarily represent common usage.
Findings: In this crossover clinical trial that included 26 healthy participants who underwent on-road driving tests, the standard deviation of lateral position (SDLP, a measure of lane weaving, swerving, and overcorrecting) at 40 to 100 minutes following vaporized consumption was 18.21 cm for CBD-dominant cannabis, 20.59 cm for THC-dominant cannabis, 21.09 cm for THC/CBD-equivalent cannabis, and was 18.26 cm for placebo. At 240 to 300 minutes, the SDLP was 19.03 cm for CBD-dominant cannabis, 20.59 cm for THC-dominant cannabis, 19.88 cm for THC/CBD-equivalent cannabis, and 19.37 cm for placebo. Compared with placebo, SDLP with THC-dominant and THC/CBD-equivalent cannabis was significantly greater at 40 to 100 minutes but not 240 to 300 minutes after consumption; there were no significant differences between CBD-dominant cannabis and placebo.
Meaning: Although this study did not find statistically significant differences in driving performance during experimental on-road driving tests between CBD-dominant cannabis and placebo, the effect size may not have excluded clinically important impairment, and the doses tested may not necessarily represent common usage.
Affiliation :
Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia